The role of chemoattractants (e.g., EGF) and surface receptors (e.g., EphA2) as driving molecules controlling cell adhesion and migration in cancer has been a focus of study for many years, and has been exploited for targeting of drug delivery and cancer treatment. This evidence concerns the gene EPHA2 and cancer.